Protalix Biotherapeutics Inc. buy stratec
Summary
This prediction ended on 05.11.21 with a price of €0.94. Massive losses of -81.68% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Protalix Biotherapeutics Inc. | -1.324% | -1.324% | -51.307% | -40.710% |
iShares Core DAX® | 0.805% | 2.118% | 15.587% | 16.559% |
iShares Nasdaq 100 | 1.995% | 4.071% | 28.811% | 56.196% |
iShares Nikkei 225® | 1.264% | -2.374% | 3.374% | 4.271% |
iShares S&P 500 | 1.637% | 2.287% | 24.187% | 46.895% |
Comments by stratec for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix is a Buy for investors who are patient and brave...
Protalix has the first FDA-approved plant cell expressed protein, Elelyso for Gaucher disease, and has three other drug candidates in its pipeline.
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). Phase 3 interim data for its Fabry disease franchise will be reported in 2018. PRX-102 has less antibody formation (and antibodies only stay in the body briefly).
The orphan disease market is lucrative with PRX-102 to potentially become the new standard of care.
stratec stimmt am 03.02.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 5.22€ zu.
In the thread Trading Protalix Biotherapeutics Inc.